JP6585167B2 - Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 - Google Patents

Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 Download PDF

Info

Publication number
JP6585167B2
JP6585167B2 JP2017517705A JP2017517705A JP6585167B2 JP 6585167 B2 JP6585167 B2 JP 6585167B2 JP 2017517705 A JP2017517705 A JP 2017517705A JP 2017517705 A JP2017517705 A JP 2017517705A JP 6585167 B2 JP6585167 B2 JP 6585167B2
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
hydroxy
substituted
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017517705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530154A5 (enExample
JP2017530154A (ja
Inventor
フェアハースト，ロビン，アレク
フュレ，パスカル
ノップフェル，トーマス
ルブラン，キャサリン
リャオ，エルブイ
マー，ロバート
ニムズガーン，ピエール
リポシュ，セバスチャン
ション，ジン
ツァオ，シャンリン
ハン，ボ
ワン，キャン
ポーター，デール
ブッシュマン，ニコール
ポータ，ダイアナ グラウス
ポータ，ダイアナ グラウス
ヘフリガー，キャロリナ
村上　雅人
雅人 村上
パルマー，マイケル
ワン，ヨウツェン
ワイス，アンドレアス
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017530154A publication Critical patent/JP2017530154A/ja
Publication of JP2017530154A5 publication Critical patent/JP2017530154A5/ja
Application granted granted Critical
Publication of JP6585167B2 publication Critical patent/JP6585167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017517705A 2014-10-03 2015-10-02 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 Active JP6585167B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/088094 2014-10-03
CN2014088094 2014-10-03
PCT/US2015/053677 WO2016054483A1 (en) 2014-10-03 2015-10-02 Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019161051A Division JP6794514B2 (ja) 2014-10-03 2019-09-04 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Publications (3)

Publication Number Publication Date
JP2017530154A JP2017530154A (ja) 2017-10-12
JP2017530154A5 JP2017530154A5 (enExample) 2018-11-15
JP6585167B2 true JP6585167B2 (ja) 2019-10-02

Family

ID=54330059

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017517705A Active JP6585167B2 (ja) 2014-10-03 2015-10-02 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
JP2019161051A Active JP6794514B2 (ja) 2014-10-03 2019-09-04 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019161051A Active JP6794514B2 (ja) 2014-10-03 2019-09-04 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Country Status (6)

Country Link
US (3) US20180185341A1 (enExample)
EP (1) EP3200786B1 (enExample)
JP (2) JP6585167B2 (enExample)
ES (1) ES2756748T3 (enExample)
PL (1) PL3200786T3 (enExample)
WO (1) WO2016054483A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019218398A (ja) * 2014-10-03 2019-12-26 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234072B (zh) * 2016-05-20 2022-11-04 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
JP7394623B2 (ja) * 2016-11-02 2023-12-08 ノバルティス アーゲー Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ
TWI723480B (zh) * 2018-07-27 2021-04-01 大陸商北京加科思新藥研發有限公司 用作fgfr4抑制劑的稠環衍生物
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
US6140338A (en) 1996-07-29 2000-10-31 Banyu Pharmaceutical, Co., Ltd. Chemokine receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
CO4980854A1 (es) 1998-02-10 2000-11-27 Novartis Ag Inhibidores de celulas b particularmente amidas, proceso par su produccion y composiciones farmaceuticas que los contiene
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
KR20020048427A (ko) * 1999-11-08 2002-06-22 폴락 돈나 엘. 이미다졸리디논 알파 ｖ 인테그린 길항제를 제조하기 위한방법 및 중간체
EP1475368A4 (en) 2002-02-14 2006-03-29 Ono Pharmaceutical Co FUSED CORE COMPOUNDS CONTAINING N-CARBAMOYL NITROGEN AND MEDICAMENTS CONTAINING SAID COMPOUNDS AS ACTIVE INGREDIENTS
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
KR100732440B1 (ko) * 2002-08-30 2007-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 질소 함유 방향환 유도체
WO2004056820A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
WO2004091485A2 (en) 2003-04-11 2004-10-28 Taigen Biotechnology Aminoquinoline compounds
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
WO2007009883A1 (en) 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines
EP1963320A1 (en) * 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
ME00011A (me) 2005-12-21 2009-02-10 Novartis Ag Derivati pirimidinilaril uree kao fgf inhibitori
CN101405002A (zh) 2005-12-29 2009-04-08 詹森药业有限公司 激肽原2受体拮抗剂
WO2007136893A2 (en) 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
WO2007141473A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
MX2009009574A (es) 2007-03-09 2009-09-16 Novartis Ag Tratamiento de melanoma.
EP2550972B1 (en) 2007-04-02 2018-02-21 Genentech, Inc. A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
WO2009079008A1 (en) 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CN102224170A (zh) 2008-09-03 2011-10-19 利琴蒂亚有限公司 抑制与fgfr4相关的癌细胞侵袭的材料和方法
WO2010027002A1 (ja) 2008-09-05 2010-03-11 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
SG175877A1 (en) 2009-05-04 2011-12-29 Plexxikon Inc Compounds and methods for inhibition of renin, and indications therefor
JP2013509442A (ja) 2009-10-29 2013-03-14 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節因子としての二環式ピリジンおよび類似体
EP2493864B1 (en) 2009-10-30 2014-10-01 Novartis AG N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
US20190192510A1 (en) 2010-02-01 2019-06-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
CA2806341C (en) 2010-07-29 2020-03-24 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
WO2012061337A1 (en) * 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
AP2013007153A0 (en) 2011-03-18 2013-09-30 Lupin Ltd Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
BR112015000653A2 (pt) 2012-07-11 2019-11-05 Blueprint Medicines Corp compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014079709A1 (en) 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR102469849B1 (ko) 2013-04-19 2022-11-23 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3019491A4 (en) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASEHEMMER FOR THE TREATMENT OF DISEASES
TW201605452A (zh) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
DK3395814T3 (da) 2013-10-25 2022-07-04 Blueprint Medicines Corp Hæmmere af fibroblastvækstfaktorreceptoren
AU2014338549B2 (en) * 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3200786B1 (en) * 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3273959A1 (en) * 2015-03-25 2018-01-31 Novartis Ag Pharmaceutical combinations
JP7394623B2 (ja) 2016-11-02 2023-12-08 ノバルティス アーゲー Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019218398A (ja) * 2014-10-03 2019-12-26 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Also Published As

Publication number Publication date
WO2016054483A1 (en) 2016-04-07
JP2019218398A (ja) 2019-12-26
US20190076412A1 (en) 2019-03-14
US10463653B2 (en) 2019-11-05
US10507201B2 (en) 2019-12-17
PL3200786T3 (pl) 2020-03-31
JP6794514B2 (ja) 2020-12-02
EP3200786B1 (en) 2019-08-28
EP3200786A1 (en) 2017-08-09
US20190231760A1 (en) 2019-08-01
US20180185341A1 (en) 2018-07-05
ES2756748T3 (es) 2020-04-27
JP2017530154A (ja) 2017-10-12

Similar Documents

Publication Publication Date Title
JP6585167B2 (ja) Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
JP6745856B2 (ja) Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体
CN101945869B (zh) 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
JP6771464B2 (ja) Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
EP2947081B1 (en) 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors
AU2022402390A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250129096A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP4926973B2 (ja) 治療化合物としての、イミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物ならびにそれらの類似体
WO2022061251A1 (en) Compounds and methods for kras modulation and indications therefor
RS59110B1 (sr) Heteroarilni sik inhibitori
JP2011513483A (ja) タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
CN102066371A (zh) 芳基-喹啉基化合物及其用途
JP2022526364A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP7339263B2 (ja) Ｊａｋ阻害剤としてのピラゾロピリミジン化合物
JP2022526176A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
TWI690528B (zh) 稠環雙環吡啶基衍生物
HK1222388B (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
HK1174038A (en) 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190904

R150 Certificate of patent or registration of utility model

Ref document number: 6585167

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250